MBX Biosciences (MBX) Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MBX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
MBX Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$60.68 |
| 52 Week High | US$66.55 |
| 52 Week Low | US$9.63 |
| Beta | 0 |
| 1 Month Change | 55.66% |
| 3 Month Change | 82.65% |
| 1 Year Change | 388.13% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 156.55% |
Recent News & Updates
MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)
Summary I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables longer-acting, less frequent dosing, addressing key safety and compliance issues in hypoparathyroidism and obesity. Canvuparatide's Phase 2 data show strong efficacy and patient benefit, but Phase 3 must address PK variability and long-term calcium control risks. MBXX's obesity pipeline offers asymmetric upside, while $440M cash extends runway into 2029, mitigating near-term financing risk. Canvuparatide's phase 3 readout comes with risk, similar to recent Eneboparatide failing phase 3 trial (although their ph2 was positive), so we see MBX as a speculative buy. Read the full article on Seeking AlphaMBX Biosciences (MBX) Stock Looks Fully Valued After New Phase 2 Data
MBX Biosciences (MBX) has drawn fresh attention after publishing full Phase 2 Avail and one-year open-label data for its lead candidate canvuparatide in chronic hypoparathyroidism, alongside confirming plans for a pivotal Phase 3 trial. See our latest analysis for MBX Biosciences. Against this backdrop, MBX Biosciences stock has seen strong momentum, with a 7 day share price return of 29.36% and a 90 day share price return of 41.01%, while the 1 year total shareholder return is very large at...Recent updates
Shareholder Returns
| MBX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.7% | -3.9% | 0.8% |
| 1Y | 388.1% | 40.9% | 20.5% |
Return vs Industry: MBX exceeded the US Pharmaceuticals industry which returned 44.2% over the past year.
Return vs Market: MBX exceeded the US Market which returned 19.6% over the past year.
Price Volatility
| MBX volatility | |
|---|---|
| MBX Average Weekly Movement | 11.8% |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MBX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MBX's weekly volatility has decreased from 19% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 63 | Steve Hoerter | mbxbio.com |
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
MBX Biosciences, Inc. Fundamentals Summary
| MBX fundamental statistics | |
|---|---|
| Market cap | US$2.69b |
| Earnings (TTM) | -US$86.61m |
| Revenue (TTM) | n/a |
Is MBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$86.61m |
| Earnings | -US$86.61m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.82 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MBX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/15 03:38 |
| End of Day Share Price | 2026/07/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MBX Biosciences, Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eliana Merle | Barclays |
| Jonathan Wolleben | Citizens JMP Securities, LLC |
| Corinne Johnson | Goldman Sachs |